AKT3 Inhibitors
1 drugsAbout AKT3
AKT3, also known as protein kinase B gamma, is a serine/threonine kinase involved in cell growth, proliferation, survival, and metabolism. As a member of the AKT family, it plays a crucial role in fundamental cellular pathways.
AKT3 is a compelling oncology target due to the dysregulation of AKT signaling observed in various cancers. Currently, there is no genetic evidence available directly linking AKT3 mutations to specific diseases.
AKT3 is targeted by one FDA-approved drug, TRUQAP (AstraZeneca), a small molecule for oncology indications. AstraZeneca is the only company with an approved AKT3-targeting drug.
Top AKT3 Drugs
AstraZeneca is currently the only company with an approved drug targeting AKT3.
The limited competitive landscape presents an opportunity for other companies to enter the AKT3 market.
AKT3 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets AKT3, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
AKT3 Clinical Trials 44 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on AKT3. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 8 | 0 | 13 | 100% |
| Phase 2 | 12 | 1 | 2 | 9 | 33% |
| Phase 3 | 11 | 0 | 0 | 11 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved AKT3 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting AKT3. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
AKT3 Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for AKT3 was TRUQAP in 2023.
The recent approval suggests a renewed interest in AKT3 as a therapeutic target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 21 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on AKT3. A trial counts if an approved drug acting on AKT3 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.